NLA 2025: Managing Omega-3 Therapy With Statins, PCSK9 Inhibitors for Cardiovascular Care
June 2nd 2025Frank Qian, MD, MPH, discusses the integration of omega-3 fatty acid therapy alongside statins and PCSK9 inhibitors in cardiovascular risk management, highlighting the distinct mechanisms of benefit and lack of significant drug interactions.
NLA 2025: Exploring the Evidence Behind Omega-3 Fatty Acids for Cardiovascular Risk
June 1st 2025Frank Qian, MD, MPH, discusses the clinical indications, dosing strategies, and cardiovascular outcomes data for prescription omega-3 fatty acids, including the ongoing debate about EPA vs EPA-DHA formulations and the implications of recent trial findings.
Emerging Data: Impacts of ROCKstar and AGAVE-201
May 30th 2025Panelists discuss how factors such as patient preferences, disease severity, organ-specific involvement, and adverse effect profiles influence the selection of second-line therapies for steroid-refractory chronic graft-vs-host disease (cGVHD) in the context of multiple FDA-approved agents.
Tailoring Therapy: Weighing Evidence, Organ Involvement, and Route of Administration
May 30th 2025Panelists discuss how factors such as patient preferences, disease severity, organ-specific involvement, and adverse effect profiles influence the selection of second-line therapies for steroid-refractory chronic graft-vs-host disease (cGVHD) in the context of multiple FDA-approved agents.
Steroid-Refractory cGVHD: A Look at FDA-Approved Options
May 30th 2025Panelists discuss how recent FDA approvals and evolving evidence for second-line treatments, including ruxolitinib, ibrutinib, and belumosudil, are reshaping chronic graft-vs-host disease (cGVHD) management by offering tailored, evidence-based options for steroid-refractory patients.
HER2 and HER3 in NSCLC: The Latest ADC Data and NCCN Guideline Updates
May 29th 2025Corrine Stahura, PharmD, and Sophia Gilardone, PharmD, BCOP, discuss recent clinical trial data and evolving guideline recommendations for HER2- and HER3-directed antibody-drug conjugates (ADCs) in non–small cell lung cancer (NSCLC), highlighting differences in efficacy, safety, and patient selection criteria.
Pharmacist Perspectives on ADC-Associated Toxicity in NSCLC Treatment
May 28th 2025Corrine Stahura, PharmD; and Sophia Gilardone, PharmD, BCOP, discuss how patient- and treatment-related factors influence the risk of severe toxicity with antibody-drug conjugates (ADCs) in non–small cell lung cancer (NSCLC).
Health Care Is a Human Right: A Roundtable on Values, Visibility, and the Work Ahead
May 27th 2025In this roundtable, 3 pharmacy faculty members reflect on how shifting federal priorities and the defunding of research initiatives have impacted their work, communities, and careers—while highlighting the power of resilience, solidarity, and reimagined academic impact in advancing public health equity.
HER2 and HER3 ADCs in Focus: Clinical Pearls for Managing Emerging Toxicities
May 27th 2025Corrine Stahura, PharmD; and Sophia Gilardone, PharmD, BCOP, discuss the distinct adverse effect profiles of HER2- and HER3-targeted antibody-drug conjugates—particularly the risk and management of interstitial lung disease—and offer practical guidance based on clinical trial data and treatment protocols.
Patient Education for LDL-C–Lowering Therapies
May 27th 2025Panelists discuss how patient education should emphasize the importance of low-density lipoprotein cholesterol (LDL-C) management, the benefits and risks of therapy intensification, and how clinicians can navigate the expanding range of LDL-C–lowering agents by considering patient-specific factors such as cardiovascular risk, prior treatments, and cost-effectiveness.
Key Takeaways to Prioritize in Practice
May 26th 2025A panelist discusses key insights for pharmacists to prioritize, including staying informed about new respiratory syncytial virus (RSV) vaccines such as Arexvy and Abrysvo, educating patients on the benefits of vaccination, monitoring common adverse effects, ensuring timely access to vaccines, and playing a crucial role in supporting patient safety and prevention efforts for RSV.
April 2025 ACIP Recommendations and Other Updates
May 26th 2025A panelist discusses recent advancements in the respiratory syncytial virus (RSV) vaccine space, including the approval of Arexvy and Abrysvo for older adults and pregnant individuals, the development of promising mRNA and protein subunit vaccines for high-risk groups, and ongoing studies to optimize dosing schedules and booster needs, all aimed at reducing RSV-related hospitalizations and deaths.
Christian John Lillis on C diff, Public Health, and the Role of Pharmacists
May 24th 2025Christian John Lillis reflects on key insights from the 2025 Peggy Lillis Foundation C diff Summit, highlighting the critical role of pharmacists in infectious disease care, persistent challenges in patient outcomes, and the need for renewed investment in public health infrastructure and policy.
C diff, Community, and Public Trust: Insights From Christian John Lillis
May 23rd 2025Christian John Lillis discusses the 2025 Peggy Lillis Foundation C diff Summit, emphasizing the enduring need for community-building among survivors, the importance of sustained public health advocacy, and the growing urgency to defend federal health agencies amid political and institutional uncertainty.
Navigating the Path to Second-Line Therapy
May 23rd 2025Panelists discuss how second-line therapy selection and individualized care strategies are essential in chronic graft-vs-host disease (cGVHD) management, emphasizing the need to reduce steroid-related toxicity, address patient-specific factors, and leverage pharmacist expertise to optimize outcomes.
Early Challenges in the cGVHD Journey
May 23rd 2025Panelists discuss how early diagnosis, evolving treatment strategies, and pharmacist-led interventions are advancing chronic graft-vs-host disease (cGVHD) management by addressing unmet needs, improving care coordination, and enhancing patient access to emerging therapies.
Expert Shares RSV Vaccination Strategies for Older Adults: Recommendations and Patient Engagement
May 21st 2025RSV vaccination for older adults requires understanding risk factors, using empathetic communication strategies, and proactively identifying eligible patients through careful review of medical histories and care transitions.